798 results about "Targeting therapy" patented technology

The invention provides a drug target affinity prediction algorithm based on protein three-mode and multi-feature fusion, and the algorithm makes full use of sequence information and two-dimensional and three-dimensional structural features of drugs and proteins, and realizes deep integration of data. The technical innovation point lies in that a multi-modal data fusion mechanism and an advanced graph neural network technology are introduced, and the sensitivity and recognition capability of the model to key biomarkers are enhanced through a dynamic attention mechanism. According to the technical advantage, the method has higher accuracy and stability when processing complex biological data, and compared with the prior art, the generalization ability and the interpretability are remarkably improved. In the aspect of technical maturity, the algorithm has passed multiple rounds of verification and shows good prediction performance and adaptability. The method is simple in operation and wide in market application prospect, can assist in new drug discovery and accelerate the drug design process, can also promote the development of the precision medical field, and particularly has important value in targeted therapy and disease prevention strategy formulation.

The invention belongs to the technical field of biomedical materials, and relates to ultrasonic response adhesion integrated hydrogel as well as a preparation method and application thereof, the hydrogel comprises a hydrogel matrix, an interface anchoring agent and a functional load component; the preparation method comprises the following steps: 1, preparing a hydrogel precursor solution, and preparing a hydrogel matrix into a solution; 2, carrying out mold molding or injection crosslinking on the solution prepared in the step 1 to form hydrogel; 3, preparing an interface anchoring agent solution, and dissolving or dispersing an interface anchoring agent in a solvent to prepare the interface anchoring agent solution; the ultrasonic responsive adhesive hydrogel platform provided by the invention can provide an efficient, controllable and universal solution for tissue adhesion, targeted therapy, wearable attachment and the like in a complex microenvironment, and is suitable for a plurality of clinical scenes such as chronic wound management, surgical postoperative closure, infection control, adhesive bioelectronic fixation, soft tissue engineering and the like.

The invention discloses a skin targeted therapy laser control method and system based on a dual-wavelength synergistic effect, and the method comprises the steps: collecting the real-time morphological characteristics and pigment distribution data of skin tissues through a multispectral imaging unit, and recognizing the optical characteristic parameters of a target treatment region; generating a dual-wavelength combination scheme through a dynamic wavelength selection algorithm based on the optical characteristic parameters and the tissue structure characteristics of the target treatment area; according to a dual-wavelength combination scheme, generating a synergistic laser sequence with a specific pulse interval and energy ratio; the synergistic laser sequence is converted into a driving signal, and a dual-wavelength laser is controlled to output composite laser; and laser output parameters are dynamically adjusted through real-time thermal diffusion monitoring and an optical feedback mechanism. By utilizing the embodiment of the invention, accurate and selective heat dissipation of skin target tissues can be realized, surrounding normal tissues are effectively protected, the treatment safety and effectiveness are improved, and side effects are reduced.

The invention discloses an application of a therapeutic target spot in preparation of a drug for treating targeted therapy resistance of kidney cancer. The therapeutic target spot is SLC27A3. The SLC27A3 comprises an SLC27A3 gene and a coding sequence thereof, an expression product of the SLC27A3 gene and a coding sequence thereof, and the SLC27A3 gene and an active fragment or derivative of the expression product thereof; the nucleotide of the SLC27A3 is as shown in SEQ ID NO. 1. According to the invention, a therapeutic target SLC27A3 is knocked out or silenced, and a compound Parishin for resisting the SLC27A3 protein is provided, so that the resistance of renal clear cell carcinoma cells to the pezopanib is remarkably improved, and the sensitivity of renal carcinoma cells to the pezopanib is enhanced.

The invention discloses a method for identifying the effectiveness of a Cas target spot by combining a gene large model and ML, and belongs to the field of biotechnology and artificial intelligence. The method comprises the following steps: constructing a detection array of A types of combined sequences and targeted combined sequences, wherein the detection array is provided with A detection units; respectively adding a combined sequence into each detection unit, carrying out incubation reaction, obtaining a fluorescence value of each detection unit, and carrying out normalization processing; carrying out key feature extraction on each combined sequence by adopting a feature extraction model; constructing a label set and a training set, constructing an integrated model, and training by adopting the label set and the training set; forming a machine learning model by the feature extraction model and the trained integrated model; and combining the new target sequence and the PAM sequence into a to-be-analyzed combined sequence, inputting the to-be-analyzed combined sequence into the machine learning model to obtain a predicted fluorescence value, and judging the recognition capability of the Cas protein on the combined sequence based on the fluorescence value. The method can assist in targeted therapy detection.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention provides an ergosterol-loaded brain-targeted nano preparation and a preparation method and application thereof, and relates to the field of nano materials and nano biological medicine.The active ingredient ergosterol of the nano preparation is entrapped in a DSPE-PEG-pinacol borate nano material, and the nano material has the ROS response characteristic and can be used for preparing a brain-targeted nano preparation. The ergosterol-loaded nano preparation is in the shape of a regular sphere, is uniform in particle size, has good dispersibility and stability, has good ability of targeted therapy of cerebral arterial thrombosis diseases, effectively solves the problems of poor targeting property, low bioavailability and the like of common drugs, enhances the therapeutic effect of ergosterol on cerebral arterial thrombosis, and has good application prospects. The ergosterol can effectively improve brain injury caused by the cerebral arterial thrombosis and has a good treatment effect, meanwhile, the ergosterol serving as the active ingredient plays a role in treating the cerebral arterial thrombosis by activating a PI3K / AKT / mTOR pathway, and a new direction is provided for treatment of the cerebral arterial thrombosis.

The invention provides an engineered membrane coated nano drug delivery system and application thereof, and belongs to the technical field of nano biomedices.The drug delivery system comprises an inner core combined with a drug, the inner core is coated with a cell membrane, based on the nano drug loading technology and the membrane coating technology, DOX and SRF are loaded on mPDA mesoporous nanoparticles, and thyroid cancer synergistic killing nanoparticles mPDS are formed; the bionic drug delivery system is characterized in that mPDS is used as a target drug delivery system, mPDS is coated with a genetically engineered tumor cell membrane, a dual-targeting membrane-coated nano drug delivery system (mPDS-coated CAR-M) is obtained, and the bionic drug delivery system can penetrate through thyroid cancer in a targeted manner, gather in a focus and reduce side effects of chemotherapy; when near-infrared irradiation is carried out on local tumor, DOX and SRF in mPDS are released, the synergistic effect of photothermal therapy-chemotherapy-targeted therapy is achieved, and the thyroid cancer is killed synergistically.

The invention discloses a leukemia targeted therapy preparation as well as a preparation method and application thereof. Comprising a DNA nanoflower carrier targeting leukemia cells through a PTK7 receptor and benzene arsenic oxide loaded on the carrier. The DNA nanoflower carrier is obtained by rolling circle amplification, and a nucleic acid aptamer complementary sequence of targeted binding leukemia cells is introduced into a template chain subjected to rolling circle amplification. The preparation method comprises the following steps: modifying sulfydryl onto a DNA nanoflower by using DNA-Dithiol, then breaking a disulfide bond by using reduced glutathione to expose the sulfydryl, and loading benzene arsenic oxide onto the DNA nanoflower through a reaction between trivalent arsenic and the sulfydryl. The structure of the DNA nanoflower has a high surface area and high porosity, and can load a large amount of PAO, so that the killing performance on cancer cells is enhanced; the aptamer sgc8 sequence is introduced into the DNA nanoflower, so that the targeting of the DNA nanoflower to cancer cells is effectively realized; the preparation also has the advantages of being good in thermodynamic stability, easy to store, excellent in biocompatibility and the like, and has a very good application prospect.

The invention provides a biological material for repairing an ovarian function as well as a preparation method and application thereof, and relates to the technical field of biological materials, a large number of experiments prove that specific biological protein components for reversing the ovarian function in extracellular vesicles are growth differentiation factor 9 (GDF-9) for repairing an ovary, and the biological material has the advantages that the ovarian repairing function mechanism of the specific biological protein components for reversing the ovarian function in the extracellular vesicles is found; according to the present invention, the GDF-9 extracellular vesicles (GDF-9Over-existed Extracellular vesicles, GOEs) are adopted as the active substance, such that the component is effectively extracted and purified so as to achieve the target of targeted therapy.

The invention discloses a mesenchymal stem cell membrane bionic nano-enzyme for targeted therapy of Parkinson's disease as well as a preparation method and application of the mesenchymal stem cell membrane bionic nano-enzyme. The mesenchymal stem cell membrane bionic nano enzyme comprises an inner core and a mesenchymal stem cell membrane, wherein the inner core is composed of mesoporous polydopamine nanoparticles, and the mesenchymal stem cell membrane coats the inner core. The medicine contains the mesenchymal stem cell membrane bionic nano enzyme. The mesenchymal stem cell membrane bionic nano-enzyme disclosed by the invention shows good biocompatibility, and can be homed to a Parkinson disease region in the brain under the mediation of CXCR4 and VLA-4 specific membrane proteins. In addition, through the CD47 membrane protein expressed on the surface, the removal of the immune system can be avoided, so that the action time in the body is prolonged. The nano-enzyme is helpful for eliminating reactive oxygen free radicals, reducing oxidative stress level and reducing damage of neuroinflammation to dopaminergic neurons, so that safe and efficient treatment of Parkinson's disease is realized.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

The invention provides a preparation method and application of a CD70 specific nano antibody molecular imaging probe. The probe comprises a tumor targeting group, radionuclide and a bifunctional chelating agent, the tumor targeting group is a CD70 specific nano antibody; the CD70 specific nano antibody is R8B4, and the amino acid sequence of the R8B4 is as shown in SEQ ID No. 1. The probe provided by the invention can realize noninvasive diagnosis of solid tumors such as renal clear cell carcinoma and malignant tumors of a blood system; reabsorption of the compound in the kidney is effectively inhibited through charge adjustment, kidney uptake is remarkably reduced, non-specific signals are reduced, the signal-to-noise ratio during targeted imaging or treatment is increased, and the imaging quality and treatment safety are improved. The probe not only has a wide application prospect in tumor diagnosis, but also provides a new technical support for targeted therapy and individualized precision medical treatment, and has important scientific research and clinical application values.

The invention provides an antibody drug conjugate property prediction method based on multi-modal fusion, and belongs to the field of bioinformatics. The method comprises the following steps: firstly, explicitly modeling sequence position information through sine position coding; secondly, introducing a bidirectional cross attention mechanism to establish interaction between a light chain and a heavy chain and alignment between an antigen and an antibody; thirdly, the integrated graph neural network reconstructs the adjacency relation according to the attention weight, and topological features are extracted; and finally, in combination with a double-stage self-adaptive refining module, two-stage treatment of alignment and refining is realized, and each modal feature contribution is adjusted in a self-adaptive manner. And meanwhile, the sequence robustness is improved through Mask perception feature extraction, and the interpretability analysis of the key binding sites is realized through the attention weight. The method can significantly improve the prediction accuracy, and can be widely applied to cancer targeted therapy and drug design optimization.

The invention relates to the field of biological medicine, in particular to a prodrug structure with ROS signal response performance and a preparation method and application thereof. The prodrug molecule with ROS signal response performance developed by the invention can quickly release living active molecules in a disease signal ROS-enriched environment, and plays a role in targeted therapy. The method has good universality, prodrug modification can be carried out on multiple molecules, four kinds of drug molecules approved to appear on the market are included, and it is verified that the solubility and biocompatibility of drugs can be improved, cytotoxicity can be reduced, and the effect of targeted therapy can be improved. Based on the structural characteristics of the molecules, the molecules can also be complexed with PVA hydrogel, and responsive controllable release of the medicine is further achieved.

The invention relates to the technical field of medicines and biology, in particular to a mouse EGFR (Epidermal Growth Factor Receptor) mutant lung adenocarcinoma cell line (EP Mus musculus) as well as preparation and application thereof. The invention provides an EP cell line ([EGFRE19delta (mutation); trp53 (deletion), EP] is derived from a lung adenocarcinoma model of a C57BL / 6 strain mouse, carries the most common EGFRE19del mutation in lung adenocarcinoma, is a first lung adenocarcinoma mouse cell line carrying EGFR mutation known in the world at present, has the in-vivo tumorigenesis ability of the C57BL / 6 strain mouse, and fills the blank of the mouse EGFR mutant cell line. The cell line provided by the invention has the background of EGFRE19del homozygous activation mutation and Trp53 homozygous deletion mutation, is sensitive to EGFR-TKI targeted therapy, can be used for in-situ tumor formation in subcutaneous and lung of an immune normal mouse C57BL / 6, and is suitable for immunotherapy and targeted therapy research of EGFR mutation lung adenocarcinoma.

The present invention relates to a local micro-scale cooling control optimization method and belongs to the field of biomedical engineering. In the method, the accurate cooling of a therapy region is realized by means of accurately controlling the release of a cryogenic medium. A micro-flow pump and a solenoid control valve are used to accurately adjust the flow and speed of the cryogenic medium, and a temperature sensor built in a probe is used to monitor the temperature of the therapy region in real time. The method further comprises a proportional-integral-derivative (PID)-based control algorithm, which dynamically adjusts the release of the cryogenic medium on the basis of real-time temperature data, so as to maintain a target therapy temperature. In addition, in the method, non-contact temperature monitoring is performed on the therapy region by means of an infrared camera, and data occurring during a therapy process is recorded, thereby optimizing a therapy effect. The technology provides a safe and accurate local cryotherapy method, which is applicable to medical therapy for dermatosis, muscle injury, inflammation, etc.

The present invention discloses a method for the preparation and application of modified extracellular vesicles specifically targeted to the kidneys. These modified extracellular vesicles are derived from fibroblastic reticular cells in the mesentery tissue and express anti-inflammatory proteins after being modified with anchor peptides. By combining the extracellular vesicles secreted from fibroblastic reticular cells in the mesentery tissue with anchor peptides, the present invention ensures the effective targeting of the exosomes to the kidneys. Additionally, through genetic engineering of fibroblastic reticular cells, the exosomes secreted by these cells can carry the target molecule, anti-inflammatory protein CD5L, achieving precise targeted therapy for the kidneys. This innovative treatment strategy holds promising potential for the treatment of sepsis-associated acute kidney injury, bringing positive impacts to patients' health.

The invention provides application of Fe3O4 nanoparticles in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicines. The invention further discloses application of the Fe3O4 nano-particles in preparation of a medicine for treating benign prostatic hyperplasia. The research result of the invention emphasizes that the ferroferric oxide nanoparticles are a promising candidate drug for targeted therapy of BPH and related prostate diseases, and new possibility is provided for treatment intervention of urinary surgery. The inventor studies the effect of the Fe3O4 nanoparticles in inhibiting benign prostatic hyperplasia. Results of the inventor show that the nanoparticles not only effectively reduce the proliferation rate of prostate cells, but also improve related biochemical indexes. Therefore, the polypeptide has potential application in treatment of prostatic hyperplasia.

The invention relates to a hepatocellular carcinoma gene knockout target library based on multiple omics and a screening method of the hepatocellular carcinoma gene knockout target library, and the gene knockout target library for precise treatment of hepatocellular carcinoma is finally obtained through data collection and integration, data screening and target verification in sequence. According to the invention, through multi-omics data integration and bioinformatics analysis, key driving genes of hepatocellular carcinoma are systematically screened, and the important effects of the genes in occurrence, development, metastasis, drug resistance and immune escape of hepatocellular carcinoma are disclosed; the genes not only deepen the understanding of the hepatocellular carcinoma molecular mechanism, but also provide important theoretical basis and potential intervention targets for the development of targeted therapy and personalized therapy strategies.

The invention discloses an application of imatinib mesylate in preparation of a targeted therapeutic drug for gastric signet ring cell carcinoma. The imatinib mesylate has an obvious inhibition effect on the growth of six patients with the pathological type of gastric signet-ring cell carcinoma, the inhibition effect is more obvious along with the increase of the concentration, the concentration and dosage dependency relationship is shown, and the half inhibitory concentration (IC50) is obviously smaller than that of a positive control drug apatinib. The medicine can play a targeted therapeutic role on the gastric signet ring cell carcinoma, and is small in toxic and side effects, economical, practical and low in cost.

The invention belongs to the technical field of nano-medicines and targeted therapy, and particularly relates to a targeted nano-system nano-drug delivery system based on mesoporous polydopamine as well as a preparation method and application thereof, in particular to an N2E4-MPDA-Gem nano-system based on mesoporous polydopamine (MPDA). A targeting nano system based on mesoporous polydopamine comprises mesoporous polydopamine nano particles loaded with pancreatic cancer chemotherapy drugs, targeting molecules N2E4 are combined with the surfaces of the mesoporous polydopamine nano particles, and phenylboronic acid coatings used for controlling drug release are arranged on the surfaces of the mesoporous polydopamine nano particles. The system adopts a modular design, can be compatible with various chemotherapeutic drugs such as oxaliplatin, irinotecan and the like, and can be flexibly coupled with different targeting antibodies such as EGFR (epidermal growth factor receptor), HER2 (human epidermal growth factor receptor) and the like. A standard preparation process and good stability provide reliable guarantee for clinical transformation, and the compound shows an excellent treatment effect in a solid tumor model represented by pancreatic cancer.

The invention discloses preparation and application of a biological material for targeted therapy of osteoarthritis, and the preparation method comprises the following steps: according to a phage screening principle, after phages are combined with cartilage cells, washing off phages which are not combined with the cartilage cells, are not firmly combined with the cartilage cells and are non-specifically combined with the cartilage cells; eluting the specifically bound bacteriophage with glycine acid; after the specific binding bacteriophage is amplified by escherichia coli, screening is carried out by utilizing a bacteriophage display technology and cartilage cells; the preparation method comprises the following steps: preparing a small-size porous microgel loaded drug by adopting a multiple Pickering emulsion template method; and grafting the screened cartilage targeting peptide to the surface of the porous hydrogel microsphere to obtain the HS-SP microsphere. According to the invention, the problem of OA targeting can be effectively solved by adopting a phage display technology, and a drug is precisely targeted and delivered to an OA lesion region; the porous hydrogel microspheres with small particle size are prepared by adopting a multiple Pickering emulsion method, so that the use of a large number of surfactants is avoided, and the efficient loading and release of drugs can be realized.

The invention discloses oral brain-targeted nanoemulsion as well as a preparation method and application thereof, and belongs to the field of biological medicine preparations. Drug molecules and a stabilizer are dispersed in oil phase molecules, and then a surfactant and water are added to prepare the nano-emulsion. Drug molecules are dispersed in oil-phase molecules and then form an oil-in-water nanoemulsion with water, so that the problems of poor stability and poor water solubility of current drug molecules are solved, the oral bioavailability of the drug is improved, fusion of different drug molecules of multiple targets is realized, the drug loading capacity of the drug molecules can be effectively ensured, and the bioavailability of the drug is improved. In addition, the drug can pass through an intestinal barrier and a blood brain barrier to be successfully delivered to a brain region to realize multi-target treatment, so that efficient treatment of multi-target brain diseases such as neurodegenerative diseases and central nervous system tumors is realized.

The invention discloses a viral ARDS prognosis evaluation system based on protein joint detection, and the system comprises a sample processing module which is used for carrying out serum standardization pretreatment; the protein detection module is used for performing iBAQ quantification of IL6ST / FOXO3 / TLR7 based on DIA mass spectrometry, defining a targeted therapy threshold value and realizing targeted quantification of the core protein; and the intelligent analysis module is used for realizing cross-age risk layering based on a multivariable logic regression model. B cell function states are reflected by combining serum IL6ST / FOXO3 / TLR7 protein expression levels, a multivariable logistic regression model is constructed, and unified risk stratification of patients of all ages from children to the elderly is achieved; by locking an IL6ST / FOXO3 / TLR7 pathway, a targeted therapy threshold is defined to directly guide targeted therapy, and immune intervention is facilitated.

The invention discloses a cancer prognosis evaluation and target recognition method based on a deep neural network, and the method comprises the steps: obtaining gene expression data, and carrying out the preprocessing of the gene expression data, and obtaining initial data; performing feature extraction processing on the initial data by using a deep neural network combining a diffusion model and an auto-encoder to obtain low-dimensional representation of gene expression features; inputting the low-dimensional expression of the gene expression characteristics into an XGBoost survival analysis model to obtain a risk value, and obtaining a cancer prognosis evaluation result according to the risk value; and performing differential expression analysis according to the risk value and the gene expression of the patient to obtain the cancer prognosis target. Visibly, according to the cancer prognosis risk assessment method and system, through the deep neural network combining the diffusion model and the auto-encoder and the XGBoost survival analysis model, accurate assessment of the prognosis risk of the cancer patient and recognition of the related target spot are achieved, and therefore a scientific basis is provided for design of personalized treatment and targeted therapy.

The invention relates to a silicon-based nano material for targeted therapy of brucellosis as well as a preparation method and application of the silicon-based nano material. The invention relates to a preparation method of a silicon-based nano material for targeted therapy of brucellosis. The preparation method comprises the following steps: (1) preparing magnetic mesoporous silica; (2) aminating the magnetic mesoporous silica, and modifying the magnetic mesoporous silica with a responsive material and yeast beta-glucan to obtain modified magnetic mesoporous silica; and (3) carrying out antibiotic loading on the modified magnetic mesoporous silica. According to the silicon-based nano material for targeted therapy of brucellosis as well as the preparation method and the application of the silicon-based nano material, the surface of magnetic macroporous mesoporous silica is modified with yeast beta-glucan capable of targeting M cells and glutathione responsive molecules, and a drug delivery system sensitive to a brucellosis environment is synthesized; the nano-carrier has targeted targeting selectivity for delivering and releasing drugs, the activity, slow release and target cell uptake efficiency of antibiotics are ensured, and the brucellosis treatment is more accurate and efficient.

Described are devices and methods for administering targeted ultrasound therapy. The device consists of a wearable housing designed to conform to a part of the user's body, with an array of ultrasound transducer units on the skin-facing side. These transducers can generate ultrasound therapy to a target therapy area of the user, with frequency, intensity, treatment area, and duration parameters optimized for a therapeutic application. Incorporated within the device is a communication system, an energy source, and a processor. The processor's role is to execute instructions, including assessing the user's health status based on received data, processing and analyzing ultrasound data to gauge transmission quality, determining if the current transmission quality is within thresholds, initiating ultrasound therapy when the conditions are right, and adjusting ultrasound therapy parameters real-time or near real-time if needed during treatment. The real-time or near real-time adjustment is made through various parameters like pulsing frequency, pulse train frequency, the number of treated spots, duration, and treatment zone area. This device provides a personalized, adaptive approach to ultrasound therapy, optimizing the treatment process for each individual user.

The invention relates to an establishment method and application of in-vitro intestinal inflammation models of mice of different ages, and relates to the technical field of biology. According to the invention, young, adult, middle-aged and old wild type (WT) and TLR4 gene deletion type (TLR4 <- / ->) mice are selected, colon tissues are cultured in vitro, inflammatory response is induced by using interleukin-1beta (IL-1beta) stimulation, an age-related intestinal inflammation model is constructed, the inflammation phenotype of the mouse model and the activity of a TLR4 / MyD88 / NF-kappa B signaling pathway are determined by comparing WT and TLR4 <- / ->, and the age-related intestinal inflammation model is constructed. The core function of the TLR4 in regulating age-dependent intestinal barrier dysfunction is defined, a regulatory network of the TLR4 in intestinal immune aging and flora-host interaction is disclosed, and an age personalized medical strategy is promoted. According to the invention, an efficient and customizable multi-age in-vitro intestinal inflammation model is constructed, and an innovative platform is provided for mechanism analysis and intervention drug screening of TLR4 targeted therapy and age-related intestinal diseases.

The invention discloses a cell lineage tracking system based on synNotch and CRISPR / Cas9 bar code technology and application thereof, the cell lineage tracking system comprises a system mGFP ligand vector for constructing Sender ligand cells and a system for constructing Receiver recipient cells, and the system comprises a synNotch receptor-rtTA fusion vector, a TetO-Cas9 expression vector, a gRNA expression vector and a Target vector library containing a Barcode sequence. A synNotch system and a CRISPR / Cas9 gene editing technology are combined with a bar code strategy, a unique bar code is generated, the contact sequence between cells is recorded, the method is compatible with a single-cell sequencing technology, transcription information of the cells is provided, long-term tracking of the contact history between the cells is achieved, the method can be used for tracking interaction and functions between the cells in a tumor microenvironment, and the application prospect is wide. Through long-term tracking and functional analysis of interaction between macrophages, especially macrophages and tumor cells, the accuracy of interaction analysis is remarkably improved, and a more accurate target spot is provided for targeted therapy.